Global Histone Deacetylase (HDAC) Inhibitors Market Insights 2029: Drivers, Challenges, and Revenue Forecast
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What CAGR And Valuation Are Anticipated For The Histone Deacetylase (HDAC) Inhibitors Market?
The market for histone deacetylase (hdac) inhibitors has been experiencing substantial growth in recent years. The market size is projected to increase from $1.23 billion in 2024 to $1.32 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.6%. Factors that contributed to growth during the historic period include increased funding for epigenetic research, a rise in cases of drug-resistant cancers, an uplift in healthcare spending, heightened usage of HDAC inhibitors in veterinary medicine, and an escalation in investments in bioinformatics.
Anticipated to witness robust growth in the near future, the market size of histone deacetylase (hdac) inhibitors is predicted to escalate to $1.76 billion by 2029, with a compound annual growth rate (CAGR) of 7.4%. This escalation during the projected period can be credited to an increase in the prevalence of neurodegenerative diseases, heightened cancer awareness, surge in investments into drug evolution, rising volume of clinical studies, and the burgeoning use of precision medicine. Significant trends expected to shape the forecast period involve technological enhancement, precision medicine, synergies in cancer immunotherapy, incorporation of digital health solutions and bioinformatic advancements.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18386&type=smp
What Market Forces Are Contributing To The Growth Of The Histone Deacetylase (HDAC) Inhibitors Market?
The surge in cases of neurodegenerative ailments is predicted to power the expansion of the histone deacetylase (HDAC) inhibitors market in the future. Neurodegenerative diseases, typified by the gradual decay and fatality of neurons within the brain and spinal cord, contribute to cognitive and motor impairments and encompasses conditions like Alzheimer’s, which is known for memory lapses and cognitive deterioration due to amyloid deposits and tau knots. The growth in neurodegenerative diseases can be credited to numerous aspects such as age, lifespan, genetic makeup, and environmental influences. Histone deacetylase (HDAC) inhibitors are being investigated as possible remedies for neurodegenerative diseases due to their capacity to adjust gene expression and deliver neuroprotective benefits. For instance, the Centers for Disease Control and Prevention, a federal entity based in the United States, asserted in August 2024 that approximately 6.7 million senior adults in the United States are currently diagnosed with Alzheimer’s disease, a statistic forecasted to nearly double by 2060. Consequently, the escalating prevalence of neurodegenerative diseases is propelling the growth of the histone deacetylase (HDAC) inhibitors market.
Which Segmentation Factors Are Critical In The Histone Deacetylase (HDAC) Inhibitors Market Analysis?
The histone deacetylase (hdac) inhibitorsmarket covered in this report is segmented –
1) By Class: Class I HDACs; Class II HDACs; Class III HDACs; Class IV HDACs
2) By Route Of Administration: Oral HDAC Inhibitors; Parenteral HDAC Inhibitors
3) By Application: Oncology; Neurology; Other Applications
4) By End User: Hospitals; Academic And Research Institutes; Pharmaceutical Companies; Other End Users
Subsegments:
1) By Class I HDACs: HDAC1; HDAC2; HDAC3; HDAC8
2) By Class II HDACs: HDAC4; HDAC5; HDAC6; HDAC7; HDAC9; HDAC10
3) By Class III HDACs (Sirtuins): SIRT1; SIRT2; SIRT3; SIRT4; SIRT5; SIRT6; SIRT7
4) By Class IV HDACs: HDAC11
What Are The Dominant Trends Currently Seen In The Histone Deacetylase (HDAC) Inhibitors Market?
Major players in the histone deacetylase (HDAC) inhibitors market are focusing on creating innovative solutions, including HDAC inhibitors for cancer therapy, to improve efficiency and decrease side effects. HDAC inhibitors, a group of medical compounds used for treating cancer, inhibit the function of HDAC enzymes that typically remove acetyl groups from histone proteins. This suppression results in increased histone acetylation, changes in chromatin structure, and altered gene expression patterns. In September 2023, Shuttle Pharmaceuticals Holdings Inc., a US-based firm specialising in the development of pioneering cancer therapies, received new patents for cancer treatment using HDAC inhibitors from the U.S. Patent and Trademark Office. These advanced inhibitors are customised to target specific HDAC enzymes involved in cancer development to interrupt deviant gene expression contributing to tumor proliferation and metastasis. These patented compounds show increased potency and selectivity, reducing off-target effects and enhancing patient safety during treatment.
Which Organizations Are At The Forefront Of The Histone Deacetylase (HDAC) Inhibitors Market?
Major companies operating in the histone deacetylase (HDAC) inhibitors market are Bristol-Myers Squibb Company, Novartis AG, Merck KGaA, Abcam plc, Pharmacyclics LLC, R&D Systems Inc., Tenaya Therapeutics Inc., Syndax Pharmaceuticals Inc., Italfarmaco SpA, InvivoGen Corporation, TCI Chemicals (India) Pvt. Ltd., 4SC AG, Medivir AB, Mirati Therapeutics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Acetylon Pharmaceuticals Inc., Oryzon Genomics SA, Xynomic Pharmaceuticals Inc., Celleron Therapeutics Ltd., Midatech Pharma PLC, Karus Therapeutics Ltd., Shenzhen Chipscreen Biosciences Co. Ltd.
Access The Complete Report Here:
Which Region Is Leading Innovation In The Histone Deacetylase (HDAC) Inhibitors Market?
North America was the largest region in the histone deacetylase (HDAC) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase (HDAC) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=18386&type=smp
Browse Through More Reports Similar to the Global Histone Deacetylase (HDAC) Inhibitors Market 2025, By The Business Research Company
Her2 Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/her2-inhibitor-global-market-report
Checkpoint Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report
Protein Inhibitor Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/protein-inhibitor-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
